• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

患者报告结局在异基因造血干细胞移植中的预后价值:一项随机营养干预试验的探索性分析。

The prognostic value of patient-reported outcomes in allogeneic hematopoietic stem cell transplantation: exploratory analysis of a randomized nutrition intervention trial.

机构信息

Department of Haematology, Oslo University Hospital, 4950 Nydalen, NO-0424, Oslo, Norway.

Department of Nutrition, Institute of Basic Medical Science, University of Oslo, Oslo, Norway.

出版信息

Ann Hematol. 2023 Apr;102(4):927-935. doi: 10.1007/s00277-023-05149-x. Epub 2023 Mar 3.

DOI:10.1007/s00277-023-05149-x
PMID:36864210
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9998318/
Abstract

Whether patient-reported outcomes (PROs) can predict overall survival (OS) and non-relapse mortality (NRM) among recipients of allogeneic stem cell transplantation (allo-HSCT), is unclear. We performed an exploratory analysis of the prognostic value of patient-reported outcomes (PROs) among 117 recipients of allogeneic stem cell transplantation (allo-HSCT) who participated in a randomized nutrition intervention trial. Cox proportional hazards models were used to investigate possible associations between PROs collected pre-allo-HSCT (baseline) using scores from the EORTC Quality of Life Questionnaire-Core 30 (QLQ-C30) and 1-year overall survival (OS), whereas logistic regression was used to study associations between these PROs and 1-year non-relapse mortality (NRM). Multivariable analyses indicated that only the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) and the European Bone Marrow Transplantation (EBMT) risk score were associated with 1-year OS. In the multivariable model including clinical-sociodemographic factors for 1-year NRM, our analysis showed that living alone (p=0.009), HCT-CI (p=0.016), EBMT risk score (p=0.002), and stem cell source (p=0.046) could be associated with 1-year NRM. Moreover, in the multivariable model, our analysis showed that only appetite loss from the QLQ-C30 was associated with 1-year NRM (p=0.026). In conclusion, in this specific setting, our analysis suggests that the commonly used HCT-CI and EBMT risk scores could be predictive for both 1-year OS and 1-year NRM, whereas baseline PROs in general were not.

摘要

异体造血干细胞移植(allo-HSCT)受者的患者报告结局(PRO)能否预测总生存(OS)和非复发死亡率(NRM)尚不清楚。我们对参加随机营养干预试验的 117 名异体 HSCT 受者的患者报告结局(PRO)的预后价值进行了探索性分析。使用 EORTC 生活质量问卷核心 30 分(QLQ-C30)的评分,Cox 比例风险模型用于研究移植前(基线)PRO 与 1 年 OS 之间的可能相关性,而逻辑回归用于研究这些 PRO 与 1 年 NRM 之间的相关性。多变量分析表明,只有造血细胞移植合并症指数(HCT-CI)和欧洲骨髓移植(EBMT)风险评分与 1 年 OS 相关。在包括 1 年 NRM 的临床社会人口统计学因素的多变量模型中,我们的分析表明,独居(p=0.009)、HCT-CI(p=0.016)、EBMT 风险评分(p=0.002)和干细胞来源(p=0.046)可能与 1 年 NRM 相关。此外,在多变量模型中,我们的分析表明,只有 QLQ-C30 的食欲丧失与 1 年 NRM 相关(p=0.026)。总之,在这种特定情况下,我们的分析表明,常用的 HCT-CI 和 EBMT 风险评分可预测 1 年 OS 和 1 年 NRM,而一般的基线 PRO 则不行。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa0c/9998318/e60d291f5a82/277_2023_5149_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa0c/9998318/e60d291f5a82/277_2023_5149_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa0c/9998318/e60d291f5a82/277_2023_5149_Fig1_HTML.jpg

相似文献

1
The prognostic value of patient-reported outcomes in allogeneic hematopoietic stem cell transplantation: exploratory analysis of a randomized nutrition intervention trial.患者报告结局在异基因造血干细胞移植中的预后价值:一项随机营养干预试验的探索性分析。
Ann Hematol. 2023 Apr;102(4):927-935. doi: 10.1007/s00277-023-05149-x. Epub 2023 Mar 3.
2
[Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].造血细胞移植特异性合并症指数对异基因造血干细胞移植后非复发死亡率和总生存率的预后影响
Zhonghua Xue Ye Xue Za Zhi. 2013 Aug;34(8):659-63. doi: 10.3760/cma.j.issn.0253-2727.2013.08.004.
3
Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.HLA 匹配相关异基因造血干细胞移植中风险评分系统的比较:一项回顾性队列研究。
Turk J Haematol. 2021 Jun 1;38(2):138-144. doi: 10.4274/tjh.galenos.2020.2020.0178. Epub 2020 Jun 16.
4
Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.联合造血细胞移植合并症指数和欧洲血液与骨髓移植组评分可更好地对接受低强度异基因造血细胞移植的高危患者进行分层。
Biol Blood Marrow Transplant. 2014 Jan;20(1):66-72. doi: 10.1016/j.bbmt.2013.10.011. Epub 2013 Oct 17.
5
Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.比较两种移植前预测模型和使用不同截断点的灵活 HCT-CI,以确定低、中、高危组:在接受 allo-RIC 的患者人群中,灵活 HCT-CI 是 NRM 和 OS 的最佳预测因子。
Biol Blood Marrow Transplant. 2010 Mar;16(3):413-20. doi: 10.1016/j.bbmt.2009.11.008. Epub 2009 Nov 14.
6
Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy.造血细胞移植特异性合并症指数(HCT-CI)能否预测移植结局?日本关东地区细胞治疗研究组的一项前瞻性多中心验证研究。
Biol Blood Marrow Transplant. 2014 Oct;20(10):1553-9. doi: 10.1016/j.bbmt.2014.06.005. Epub 2014 Jul 15.
7
Patient age and donor HLA matching can stratify allogeneic hematopoietic cell transplantation patients into prognostic groups.患者年龄和供者 HLA 匹配可将异基因造血细胞移植患者分层为预后组。
Eur J Haematol. 2022 Dec;109(6):672-679. doi: 10.1111/ejh.13850. Epub 2022 Sep 10.
8
Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT.既往合并症与异基因造血细胞移植结局的关联。来自欧洲血液与骨髓移植协会(EBMT)的一项回顾性分析。
Bone Marrow Transplant. 2022 Feb;57(2):183-190. doi: 10.1038/s41409-021-01502-8. Epub 2021 Oct 30.
9
Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study.首次造血干细胞移植后复发的血液病患者进行第二次造血异体干细胞移植的预后因素:一项单中心研究。
Front Immunol. 2023 Jan 4;13:1066748. doi: 10.3389/fimmu.2022.1066748. eCollection 2022.
10
Pretransplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Nonrelapse Mortality in Allogeneic Hematopoietic Cell Transplantation.移植前血浆 ST2 水平作为异基因造血细胞移植后 1 年非复发死亡率的预后生物标志物。
Transplant Cell Ther. 2023 Feb;29(2):97.e1-97.e6. doi: 10.1016/j.jtct.2022.11.009. Epub 2022 Nov 11.

引用本文的文献

1
The Critical Exploration into Current Evidence behind the Role of the Nutritional Support in Adult Patients Who Undergo Haematogenic Stem Cell Transplantation.成人血液系统干细胞移植患者营养支持作用的当前证据的批判性探索。
Nutrients. 2023 Aug 11;15(16):3558. doi: 10.3390/nu15163558.
2
Predictive value of health-related quality of life on radiotherapy-related toxicities in patients with head and neck cancer.健康相关生活质量对头颈部癌症患者放射治疗相关毒性的预测价值。
Support Care Cancer. 2023 Apr 14;31(5):268. doi: 10.1007/s00520-023-07736-0.

本文引用的文献

1
Living alone as a risk factor for cancer incidence, case-fatality and all-cause mortality: A nationwide registry study.独居作为癌症发病率、病死率和全因死亡率的危险因素:一项全国性登记研究。
SSM Popul Health. 2021 Jun 11;15:100826. doi: 10.1016/j.ssmph.2021.100826. eCollection 2021 Sep.
2
Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN study.患者报告的疲劳可改善高危骨髓增生异常综合征 (MDS) 的预后:MDS-CAN 研究。
Br J Haematol. 2021 Jul;194(2):319-324. doi: 10.1111/bjh.17537. Epub 2021 May 31.
3
Patient-Reported Outcomes as Independent Prognostic Factors for Survival in Oncology: Systematic Review and Meta-Analysis.
患者报告结局作为肿瘤学中生存的独立预后因素:系统评价和荟萃分析。
Value Health. 2021 Feb;24(2):250-267. doi: 10.1016/j.jval.2020.10.017. Epub 2021 Jan 6.
4
How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT.自 20 世纪 80 年代以来,异基因干细胞移植相关死亡率改善了多少?来自 EBMT 的回顾性分析。
Blood Adv. 2020 Dec 22;4(24):6283-6290. doi: 10.1182/bloodadvances.2020003418.
5
Social Inequalities in Cancer Survival in Belgium: A Population-Based Cohort Study.比利时癌症生存中的社会不平等:一项基于人群的队列研究。
Cancer Epidemiol Biomarkers Prev. 2021 Jan;30(1):45-52. doi: 10.1158/1055-9965.EPI-20-0721. Epub 2020 Oct 20.
6
Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review.癌症国际随机临床试验中患者报告结局的预后价值:系统评价。
Lancet Oncol. 2019 Dec;20(12):e685-e698. doi: 10.1016/S1470-2045(19)30656-4.
7
Body weight, body composition and survival after 1 year: follow-up of a nutritional intervention trial in allo-HSCT recipients.体重、身体成分与 1 年后的生存:异基因造血干细胞移植受者营养干预试验的随访。
Bone Marrow Transplant. 2019 Dec;54(12):2102-2109. doi: 10.1038/s41409-019-0638-6. Epub 2019 Aug 27.
8
Patient-reported outcomes as predictors of survival in patients with bowel cancer: a systematic review.患者报告结局作为结直肠癌患者生存预测指标的系统评价。
Qual Life Res. 2019 Nov;28(11):2871-2887. doi: 10.1007/s11136-019-02255-0. Epub 2019 Jul 30.
9
The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials.健康相关生活质量作为预测胶质瘤患者总生存和无进展生存的预后指标的附加值:一项基于随机对照试验个体患者数据的荟萃分析。
Eur J Cancer. 2019 Jul;116:190-198. doi: 10.1016/j.ejca.2019.05.012. Epub 2019 Jun 13.
10
Effects of individualized nutrition after allogeneic hematopoietic stem cell transplantation following myeloablative conditioning; a randomized controlled trial.清髓性预处理后异基因造血干细胞移植后个体化营养的效果;一项随机对照试验。
Clin Nutr ESPEN. 2018 Dec;28:59-66. doi: 10.1016/j.clnesp.2018.08.002. Epub 2018 Aug 29.